Recruiting

Get Moving Trial

Sponsor:

University of Washington

Code:

NCT06040762

Conditions

Bladder Cancer

Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Renal Pelvis and Ureter Urothelial Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Best Practice

Exercise Intervention

App-Based Intervention

App-Based Intervention

Interview

Study Details

Brief summary:

Prehabilitation refers to the process of improving a patient's functional capabilities prior to a surgical procedure with the goal of decreasing post-surgical inactivity and physical decline. This clinical trial evaluates the utility of a personalized home-based prehabilitation exercise intervention for the improvement of physical function and surgical outcomes in patients with urothelial carcinoma undergoing definitive or consolidative surgery of the bladder (radical cystectomy) or upper tract (nephroureterectomy, ureterectomy) with or without preceding neoadjuvant/systemic therapy. The exercise intervention includes at-home exercise sessions focused on the improvement of core strength and balance as well as personalized step count goals, delivered to patients remotely via a smart-device-based application (ExerciseRx). Encouraging physical activity before surgery may improve physical function and surgical outcomes in patients who are scheduled to undergo surgery for their bladder or urothelial cancer.

Conditions

Bladder Cancer

Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Renal Pelvis and Ureter Urothelial Carcinoma

Study ID

NCT06040762

Start date

Dec 19, 2023

Status verified date

Aug, 2026

Completion date

Apr 30, 2027

Anticipated

Primary completion date

Apr 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • 18 years of age or older
  • English-speaking
  • Planned treatment with radical cystectomy or radical nephroureterectomy/ureterectomy with or without preceding systemic therapy as indicated by the patient's surgeon with enough time to complete a minimum of 4 weeks of exercises before surgery if enrolled in the (P)REHAB arm
  • Willing and able to participate in trial activities

Exclusion Criteria:

  • Cognitive/mental impairment that will preclude ability to participate in routine exercise activities. Significant cognitive or memory impairment or baseline dementia that would preclude a patient's ability to follow instructions or reproduce exercises
  • Immobility, inability/unwillingness to perform personalized exercise program. Inability to perform exercises safely from seated or standing position at home or recent falls or high fall risk. Neurologic or orthopedic condition(s) that restricts participation in unsupervised home exercises, such as prior stroke with neurologic impairment, weight-bearing precautions, or unwillingness to participate in exercises
  • Participants who have nonmuscle-invasive urothelial cancer of the bladder/upper tract anticipating undergoing organ-preserving treatments, or radiographic evidence of metastatic disease involving other organs including brain metastases.
  • Patients with predominant histology other than urothelial carcinoma of the bladder or upper tracts (e.g. metastasis from another cancer) who would not otherwise be considered candidates for standard definitive or consolidative surgeries (radical cystectomy, ureterectomy, radical nephroureterectomy) with/without treatment with preoperative/neoadjuvant systemic therapy.
  • Uncontrolled or concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study
  • Inability to understand or read English
  • Lack of access or lack of sufficient facility to use an Android or iOS smart device with the minimum criteria for using ExerciseRx
  • Not receiving surgery at UWMC
  • Participation in a clinical trial that does not permit enrollment in the Get Moving trial

Study Design

Enrollment

128 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Arm A ([P]REHAB intervention)

Starting at least 4 weeks prior to date of surgery, patients use the ExerciseRx app to follow the (P)REHAB exercise program, which consists of four 20-30 minute home exercise sessions per week and personalized step count goal setting and tracking, while receiving SOC chemotherapy, if applicable, prior to SOC surgery and for 90 days following surgery (total \~4-7 months). Patients also download the FitBit app and wear a FitBit throughout the study.

active comparator: Arm B (standard of care)

Patients receive SOC educational materials and, starting at least 4 weeks prior to date of surgery, patients wear a FitBit and use the FitBit app while receiving SOC chemotherapy, if applicable, prior to SOC surgery.

Interventions

Best Practice

Receive SOC educational materials

Exercise Intervention

Receive (P)REHAB exercise program

App-Based Intervention

Use ExerciseRx app

App-Based Intervention

Use FitBit app

Interview

Ancillary studies

Wearable Activity Tracker

Wear FitBit

Physical Performance Testing

Ancillary studies

Questionnaire Administration

Ancillary studies

Primary outcome measure

  • Trial recruitment [ Time Frame: At enrollment ]
  • Trial retention [ Time Frame: Through study completion, on average 4-7 months ]
  • Change in physical function [ Time Frame: From enrollment (T1) to 1-4 months post enrollment (before surgery) (T2) ]
  • Change in physical function [ Time Frame: From 1-4 months post enrollment (before surgery) (T2) to 4-7 months post enrollment (90 days post surgery) (T3) ]
  • Change in physical function [ Time Frame: From enrollment (T1) to 4-7 months post enrollment (90 days post surgery) (T3) ]

Central Contacts and Locations

Central contacts

Get Moving Research Coordinator

206-210-4040GetMoving@uw.edu

Locations

Fred Hutch/University of Washington Cancer Consortium

Recruiting

Seattle, Washington, United States, 98109

Contacts

Get Moving Research Coordinator

206-210-4040GetMoving@uw.edu

Principal Investigator:

Sarah Psutka

More Information

Sponsor

University of Washington

Last update posted

Aug 20, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of Washington on 2026-08-20.